TY - JOUR
T1 - First diagnostic criteria for atopic myelitis with special reference to discrimination from myelitis-onset multiple sclerosis
AU - Isobe, Noriko
AU - Kanamori, Yuji
AU - Yonekawa, Tomomi
AU - Matsushita, Takuya
AU - Shigeto, Hiroshi
AU - Kawamura, Nobutoshi
AU - Kira, Jun Ichi
N1 - Funding Information:
T.M. received a grant and payment for manuscript preparation and development of educational presentations from Bayer Schering Pharma, and also received a payment for development of educational presentations from Mitsubishi Tanabe Pharma. J.K. is an advisory board member for Merck Serono and a consultant for Biogen Idec Japan. He has received payment for lectures from Bayer Schering Pharma, Cosmic Cooperation and Biogen Idec Japan. This work was supported in part by a Health and Labour Sciences Research Grant on Intractable Diseases (H22-Nanchi-Ippan-130 and H23- Nanchi-Ippan-017) from the Ministry of Health, Labour, and Welfare, Japan, and a Scientific Research B Grant (No. 22390178) and a Challenging Exploratory Research Grant (No. 23659459) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.
Funding Information:
This work was supported in part by a Health and Labour Sciences Research Grant on Intractable Diseases ( H22-Nanchi-Ippan-130 and H23-Nanchi-Ippan-017 ) from the Ministry of Health, Labour, and Welfare, Japan , as well as a Scientific Research B Grant (No. 22390178 ) and a Challenging Exploratory Research Grant (No. 23659459 ) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan .
PY - 2012/5/15
Y1 - 2012/5/15
N2 - Objective: To establish the first evidence-based diagnostic criteria for atopic myelitis (AM) enabling it to be discriminated from myelitis-onset multiple sclerosis (MS), which is a difficult differential diagnosis. Methods: Sixty-nine consecutive AM patients examined from 1996 to 2010 at Kyushu University hospital, who fulfilled the empirical definition of AM (2003), and 51 myelitis-onset MS patients in whom allergen-specific IgE was measured, were enrolled. The first available brain MRI findings were compared between the two. Then, we compared the clinical and laboratory features between the 16 AM cases who did not meet the Barkhof brain MRI criteria for MS after more than 5 years follow-up and 51 myelitis-onset MS cases. Based on the discriminative findings, we established diagnostic criteria for AM and calculated the sensitivity and specificity. Results: AM patients had a significantly lower frequency of Barkhof brain lesions on baseline MRI than myelitis-onset MS patients. AM patients had a significantly higher frequency of present and/or past history of atopic disease and hyperIgEemia, and higher cerebrospinal fluid levels of interleukin 9 and CCL11/eotaxin, but a lower frequency of oligoclonal IgG bands than myelitis-onset MS patients. Our proposed diagnostic criteria for AM demonstrated 93.3% sensitivity and 93.3% specificity for AM against myelitis-onset MS, with 82.4% positive predictive value and 97.7% negative predictive value. Conclusion: Our first evidence-based criteria for AM show high sensitivity and specificity, and would be useful clinically.
AB - Objective: To establish the first evidence-based diagnostic criteria for atopic myelitis (AM) enabling it to be discriminated from myelitis-onset multiple sclerosis (MS), which is a difficult differential diagnosis. Methods: Sixty-nine consecutive AM patients examined from 1996 to 2010 at Kyushu University hospital, who fulfilled the empirical definition of AM (2003), and 51 myelitis-onset MS patients in whom allergen-specific IgE was measured, were enrolled. The first available brain MRI findings were compared between the two. Then, we compared the clinical and laboratory features between the 16 AM cases who did not meet the Barkhof brain MRI criteria for MS after more than 5 years follow-up and 51 myelitis-onset MS cases. Based on the discriminative findings, we established diagnostic criteria for AM and calculated the sensitivity and specificity. Results: AM patients had a significantly lower frequency of Barkhof brain lesions on baseline MRI than myelitis-onset MS patients. AM patients had a significantly higher frequency of present and/or past history of atopic disease and hyperIgEemia, and higher cerebrospinal fluid levels of interleukin 9 and CCL11/eotaxin, but a lower frequency of oligoclonal IgG bands than myelitis-onset MS patients. Our proposed diagnostic criteria for AM demonstrated 93.3% sensitivity and 93.3% specificity for AM against myelitis-onset MS, with 82.4% positive predictive value and 97.7% negative predictive value. Conclusion: Our first evidence-based criteria for AM show high sensitivity and specificity, and would be useful clinically.
UR - http://www.scopus.com/inward/record.url?scp=84859438284&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859438284&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2012.02.007
DO - 10.1016/j.jns.2012.02.007
M3 - Article
C2 - 22364869
AN - SCOPUS:84859438284
SN - 0022-510X
VL - 316
SP - 30
EP - 35
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
IS - 1-2
ER -